Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Ophthalmic Clinical Trials

Formycon Plans Ranibizumab Filings With Ustekinumab And Aflibercept In The Wings

  • News

Executive Summary

Formycon will follow a US filing for ranibizumab before the end of this year with a European submission early in 2020 as it continues work on biosimilar ustekinumab and aflibercept.

You may also be interested in...



Formycon Delay Pushes Back Coherus’ Ranibizumab

Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.

Formycon Begins Biosimilar Ustekinumab Trial

Formycon has become the latest firm to announce a Phase I trial for a proposed biosimilar ustekinumab rival to Janssen’s Stelara, following hot on the heels of NeuClone.

Sandoz Reveals Biosimilar Denosumab Program

As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin

Topics

Related Companies

Tags:
Biosimilars Ophthalmic Clinical Trials
Latest Headlines

Celltrion And Rani Partner For Oral Adalimumab

Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico

MGC And GlycoNex Kick Off Denosumab Trial In Japan

Neuraxpharm Brings In Greek Olanzapine Brand

See All
UsernamePublicRestriction

Register

GB140356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By